七月 2026
- Home
- ALK
七月 2026的ALK市场份额分析
ALK-Abelló A/S, also commonly known as ALK, is a Denmark-based pharmaceutical company which specializes in the development and manufacturing of allergy immunotherapy products for the prevention and treatment of allergy.
ALK(包含公司地区分支机构)
查看更多网站流量和参与度信息- alk.net
ALK收入截至 七月 2026为 500M - 1B
ALK主要域名产生的收入
3 年中ALK主要域名的收入
ALK主要域名的收入
ALK热门域名的总访问量
了解ALK市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
ALK热门域名的平均访问时长
分析ALK参与度指标。
过去 3 个月的平均访问时长
子公司明细
ALK热门域名的平均页面浏览量
了解ALK如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
ALK 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻Henriette Mersebach left ALK company. as executive vice president, research and development on Jan 1st '26.Danish allergy immunotherapy specialist ALK Abello(ALKB: DC) has announced that Henriette Mersebach will step down imminently as executive vice president, research and development, and as a member of the board.
二月 20, 2026阅读更多
新闻ALK company. invests into Allegriatx $5.1M in Seed 1.ALLEGRIA Therapeutics, a biotech company redefining the treatment landscape of therapeutics for mast cell-mediated diseases, has secured USD 5.1 million in its seed extension financing led by ALK Abelló.
十二月 12, 2025阅读更多
新闻ALK company. launched EURneffy in Germany on Jun 1st '25.Its partner ALK-Abelló has launched EURneffy in Germany in June 2025 with plans to launch in the U.K. later this year.
十一月 3, 2025阅读更多
查看 ALK 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。
